Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer.
about
Using the free-to-total prostate-specific antigen ratio to detect prostate cancer in men with nonspecific elevations of prostate-specific antigen levelsProstate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of CancerThe relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative GroupEndocrine treatment of prostate cancer - recent developments and the future. Part 1: maximal androgen blockade, early vs delayed endocrine treatment and side-effects.Prostate-specific antigen reduction after empiric antibiotic treatment does not rule out biopsy in patients with lower urinary tract symptoms: prospective, controlled, single-center study.Direct and multiplex quantification of protein biomarkers in serum samples using an immuno-magnetic platform.The clinical impact of different assays for prostate specific antigen.Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.Tomato sauce supplementation and prostate cancer: lycopene accumulation and modulation of biomarkers of carcinogenesis.The Japanese guideline for prostate cancer screening.Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.Predicting prostate cancer many years before diagnosis: how and why?Screening for prostate cancer using serum prostate-specific antigen: a randomised, population-based pilot study in FinlandPrediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.Stability of total and free prostate specific antigen in serum submitted to intermittent cold storage conditionsTumor markers in prostate cancer I: blood-based markers.Adding free to total prostate-specific antigen levels in trials of prostate cancer screeningProspective observational study to assess value of prostate specific antigen as screening test for prostate cancerApplications of emerging molecular technologies in glioblastoma multiformeMean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening.Development of peptides specifically modulating the activity of KLK2 and KLK3.Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and contextBiomarkers in prostate cancer surveillance and screening: past, present, and future.Screening for prostate cancer: an update.Prostate specific antigen for early detection of prostate cancer: longitudinal study.Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancerProteomic approaches in neuroblastoma: a complementary clinical platform for the future.Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control studyRisk-based prostate cancer screening.Implementation of PSA-based active surveillance in prostate cancer.Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 microg/L: are they useful tools for early detection and screening of prostate cancer?Biomarker development, from bench to bedside.KLK-targeted Therapies for Prostate Cancer.Can the Free/Total PSA Ratio Predict the Gleason Score Before Prostate Biopsy?Association of free PSA percent, total PSA, age, and gland volume in the detection of prostate cancer.Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial.Lead time associated with screening for prostate cancer.Elevated prostate specific antigen and reduced 10-year survival among a cohort of Danish men consecutively referred from primary care to an urological department during 2005-2006.Prostate-specific antigen, clinical use and staging: an overview.
P2860
Q24550631-56176B18-6DAA-495A-A228-E499DD1865CDQ28343880-17DD2759-FE66-4C6B-B0A9-B0BCC5979D49Q28749313-998236CB-7236-4759-99E2-8CECFB5DCCF1Q33610869-08A1D4A5-9580-4464-B0D2-81F266B994BBQ33739100-DCC567D9-EC43-470D-8A6B-3EFDB2B24BB7Q33814117-960AD5F7-42A9-4EF8-8075-5AD62844910CQ34022442-C8C0F804-F244-4340-8FFC-2D6078671C83Q34041688-102839EB-FB00-4219-B5AB-EA6DF410560DQ34130128-3E2DF90A-761C-4B76-B786-4708BDF4689CQ34528806-CF15B47B-DE87-409F-8D49-3C317AE246A1Q34606240-7735D061-F895-452E-8F4A-7A6D44F0F067Q35089983-79AF3679-7476-4704-A104-9D1349645220Q36026045-CA59CCFA-EF90-43BA-BDB9-4F4C1BC2DA7FQ36135888-B78E8059-7A21-48F4-98D4-6179D56F1333Q36142693-1A32106D-09DD-40A8-8086-C70591048CD9Q36263432-B79F15C7-247A-475D-A91D-E939607C0016Q36607766-DC394C04-9E57-4E15-84B6-C6A04A1D171FQ36621170-41534497-D5B0-44F6-AECA-9482FF5869D2Q36905569-D43DC28E-BC81-411A-96A4-E0F38EDC44F8Q36965370-FC487896-CEDE-4180-8362-9EB0DC9E54FDQ37160706-FE331AC2-F3EA-4A8E-8B81-1EFD7DE3A737Q37216674-5C0D9B3B-DF8A-47E7-B6B8-A47E689FC6D1Q37288832-FB9769DD-61FE-4DB5-A62A-55099B382A45Q37300931-288EDB7D-32DE-44B2-921A-83E4C670FAF9Q37338478-9AA0B482-7E01-40A5-A265-FD5D20F77596Q37362535-AE0AA936-5C5D-4A57-BD36-DE4FEF50B86AQ37422990-EEB31855-7B2B-413E-A4D5-00703F0FBF03Q37579903-E2C9AFCB-C226-46AD-9E9D-EF673798397CQ37600503-7CFE1990-17CE-489D-AEB1-2EF22E68ED4FQ37963657-05CE1BC5-4FEE-4720-8C8F-F551FB2E48EAQ38239830-25956E48-F146-4323-B901-522A23A3316EQ38460250-62A0EDC3-CA8D-48F5-A34F-473B97F6152CQ38569348-CD6BA672-AA5E-4D81-A14E-14D2F934F22BQ38967486-256C20DE-3393-44E8-B2F7-A52B14BE6A1DQ38971191-892A8612-2E7F-4854-B78E-BC7ADE46D11EQ39508313-98BDAA88-CB7A-49B6-9979-F5AE0F089E58Q39589717-EA6ACCBB-11FB-4D42-9BF8-AF9ECAFE676EQ39669271-6937F3E9-835A-4641-9EAB-867A53F3A52AQ40529859-D6B82E8D-3C10-4BF0-9067-7A9996162043Q41409507-19C3E68D-3A7D-48F2-83F8-19D2DA85EDFD
P2860
Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh
1994年學術文章
@zh-hant
name
Serum concentrations of prosta ...... diagnosis of prostate cancer.
@en
Serum concentrations of prosta ...... diagnosis of prostate cancer.
@nl
type
label
Serum concentrations of prosta ...... diagnosis of prostate cancer.
@en
Serum concentrations of prosta ...... diagnosis of prostate cancer.
@nl
prefLabel
Serum concentrations of prosta ...... diagnosis of prostate cancer.
@en
Serum concentrations of prosta ...... diagnosis of prostate cancer.
@nl
P2093
P1433
P1476
Serum concentrations of prosta ...... diagnosis of prostate cancer.
@en
P2093
P304
P356
10.1016/S0140-6736(94)90405-7
P407
P577
1994-12-01T00:00:00Z